Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives $31.80 Consensus PT from Brokerages

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) has received a consensus rating of “Moderate Buy” from the seven ratings firms that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating on the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $32.00.

A number of research firms recently commented on CRVS. Barclays lifted their price target on Corvus Pharmaceuticals from $16.00 to $28.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Corvus Pharmaceuticals in a research note on Wednesday, January 21st. Oppenheimer reaffirmed an “outperform” rating and set a $33.00 target price (up from $32.00) on shares of Corvus Pharmaceuticals in a report on Friday. HC Wainwright lifted their target price on Corvus Pharmaceuticals from $11.00 to $27.00 and gave the stock a “buy” rating in a research report on Tuesday, January 20th. Finally, Wall Street Zen downgraded Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday.

Corvus Pharmaceuticals Price Performance

NASDAQ CRVS opened at $15.32 on Thursday. The company has a market capitalization of $1.28 billion, a price-to-earnings ratio of -30.64 and a beta of 0.78. Corvus Pharmaceuticals has a 12 month low of $2.54 and a 12 month high of $26.95. The company’s fifty day moving average price is $16.46 and its two-hundred day moving average price is $10.57.

Corvus Pharmaceuticals (NASDAQ:CRVS) last released its earnings results on Thursday, March 12th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.01). As a group, analysts anticipate that Corvus Pharmaceuticals will post -0.63 EPS for the current year.

Institutional Trading of Corvus Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the business. Orbimed Advisors LLC raised its holdings in shares of Corvus Pharmaceuticals by 3.2% during the second quarter. Orbimed Advisors LLC now owns 7,165,006 shares of the company’s stock worth $28,660,000 after purchasing an additional 221,352 shares during the period. Vanguard Group Inc. lifted its position in shares of Corvus Pharmaceuticals by 5.8% in the 3rd quarter. Vanguard Group Inc. now owns 3,471,925 shares of the company’s stock worth $25,588,000 after buying an additional 191,216 shares during the last quarter. State Street Corp boosted its holdings in shares of Corvus Pharmaceuticals by 177.1% in the 4th quarter. State Street Corp now owns 2,788,223 shares of the company’s stock valued at $21,469,000 after buying an additional 1,781,904 shares during the period. MPM Bioimpact LLC acquired a new position in shares of Corvus Pharmaceuticals in the 4th quarter valued at about $21,126,000. Finally, Foresite Capital Management VI LLC grew its position in shares of Corvus Pharmaceuticals by 9.5% during the 2nd quarter. Foresite Capital Management VI LLC now owns 1,731,233 shares of the company’s stock valued at $6,925,000 after buying an additional 150,000 shares during the last quarter. Institutional investors own 46.64% of the company’s stock.

Corvus Pharmaceuticals News Roundup

Here are the key news stories impacting Corvus Pharmaceuticals this week:

• Positive Sentiment: Oppenheimer reaffirmed an “outperform” rating and raised its price target to $33 (from $32), implying substantial upside from current levels — a clear analyst vote of confidence that can support longer‑term buying interest. Oppenheimer Rating/Price Target
• Positive Sentiment: Company announced positive safety and efficacy data from cohort 4 of soquelitinib in a Phase 1 atopic dermatitis trial, including responses in patients with prior systemic therapy — this clinical progress materially de‑risks the program and supports future value for the pipeline. Atopic Dermatitis Trial Data
• Neutral Sentiment: Corvus released its Q4 2025 results and held an earnings call; management highlighted strategic advances tied to the pipeline and provided a business update, but the call materials are a mixed read for near‑term revenue prospects. Earnings Call Highlights
• Negative Sentiment: Q4 EPS came in at ($0.15), missing consensus by $0.01 — a small miss but enough to pressure sentiment in the absence of immediate revenue drivers; this likely contributed to the intraday pullback. Earnings Miss / Transcript
• Neutral Sentiment: Reported short‑interest updates in recent days show anomalous/zero values and appear unreliable — there is no clear evidence of a near‑term short squeeze or meaningful short pressure based on the published figures. (No actionable link available.)

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation immuno-oncology therapies. The company’s research efforts are centered on harnessing both the innate and adaptive immune systems to counteract tumor-driven immunosuppression. By targeting key pathways that regulate immune cell function, Corvus aims to create novel agents that can be combined with existing cancer treatments to improve patient outcomes.

Corvus’s lead pipeline candidates include small-molecule and antibody therapies designed to inhibit the adenosine pathway, a known mediator of tumor immune escape.